NIH funding opportunities

15 January 2025 (#02)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

1) *Generic Grant Writing Workshop and then the*

2) NIH Grant Writing Workshop

To prepare an application can take 4-18 months.

From submission to receiving a Notice of Award can take 10 months

Important Notices

NOT-HS-25-006 New "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2025. The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form
- PHS Assignment Request Form
- PHS 398 Cover Page Supplement Form

Application guides for FORMS-I application packages will be posted to the How to Apply - Application Guide page in November 2024.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **PA-25-301** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **PA-25-303** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **PA-25-305** Research Project Grant (Parent R01 Clinical Trial Required)
- **PA-25-302** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **PA-25-304** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **PA-25-306** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **PA-25-307** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

NOT-AI-24-085 Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes. The objective of this NOSI is to stimulate multidisciplinary collaborations between transplant immunologists and gene editing experts that explore the use of SCGE technology to address unmet needs in transplantation, such as the prevention or treatment of rejection; achievement of transplant tolerance; prolongation of allograft survival; protection from the toxicities of pharmacologic immunosuppression; and improvements in organ/cellular function of transplanted grafts. The intent of this NOSI is to encourage novel collaborations across disciplines and enhance research outcomes in a dynamic, technically challenging, and potentially high-risk/high-reward area. Ideally, such partnerships will have a lasting impact and drive the field forward beyond the lifetime of this NOSI. This notice applies to due dates on or after February 5, 2025 and subsequent receipt dates through November 16, 2027.

Notice of Funding Opportunity (NOFO)

RFA-AI-24-023 U.S.-South Africa Program for Collaborative Biomedical Research – Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional). The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science. The hallmark of the U.S.-South Africa program is the development of collaborative partnerships between South African investigators and United States (U.S.) investigators. Through international collaboration, this research will advance scientific discoveries, promote sharing of technologies and approaches, and serve local public health needs and priorities in support of global HIV/AIDS research.
AIDS Date: March 12, 2025. All applications are due by 5:00 PM local time of applicant organization. **Letter of Intent:** 30 days prior to the application due date.
Budget: Issuing IC and partner components intend to commit an estimated total of $3.8 million to fund 8-10 awards. Application budgets are not expected to exceed $400,000 in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Important Notice: All potential applicants **MUST** inform the Grants Management Office **before** 12 January 2025 of their intention to apply. This must include the specific aims, participating institutions and list of all key personnel and consultants. Only after receiving this internal letter of intent, meetings with the PI will be scheduled and project plans will be prepared. **Please also contact the Scientific Program officials** listed in the NOFO to ensure that your application is responsive to the call.

PAR-25-158 Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional). This NOFO focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (PAR-25-159***, the R34 option***).

Date: February 19, 2025 through to October 19, 2026. All applications are due by 5:00 PM local time of applicant organization.
Budget: For the R61 phase, the combined budget for direct costs during the two-year project period may not exceed $350,000 with no more than $225,000 requested in a single year. For the R33 phase, the direct costs must not exceed $500,000 per year. The project period is limited to 2 years for the R61 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

PAR-25-177 Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required). This NOFO seeks to support well-powered clinical trials consistent with NIMH's priorities for: 1) optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation

strategies that support the delivery and sustainability of optimized interventions in accessible settings. Applications responsive to this NOFO are hybrid effectiveness implementation trials that examine the effectiveness and clinical impact of interventions to prevent or treat mental illness, implementation challenges and strategies within the intervention setting, and at least one mechanism of action associated with an intervention and/or implementation strategy. The research covered under this announcement addresses practice-relevant questions and must be conducted within accessible intervention settings where the typical consumer can be identified as in need of care and be readily connected to an intervention.

Date: February 14, 2025 through to October 15, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: IMH intends to commit a total of $27,000,000 million for FY 2026 to fund this NOFO and the companion NOFOs listed in Part 1. Overview Information. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years; however, applicants are strongly encouraged to consider efficiencies and projects of shorter duration, as feasible.

PAR-25-178 Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 – Clinical Trial Required). This NOFO seeks pilot hybrid effectiveness implementation research consistent with NIMH's priorities for: 1) refining and optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of evidence supported interventions in accessible settings. This NOFO supports pilot research designed to generate the preliminary data needed as a prerequisite to a well powered clinical trial. This includes research designed to assess the feasibility, acceptability, safety, and fit of approach, and explore the impact of the approach on both the outcomes of interest and at least one hypothesized mechanism of action. Support for well powered hybrid effectiveness implementation studies is provided through separate NOFOs that are described on the NIMH Support for Clinical Trials web page.
Date: February 14, 2025 through to October 15, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: NIMH intends to commit a total of $27,000,000 for FY 2026 to fund this NOFO and the companion NOFOs Future year amounts will depend on annual appropriations. Direct costs are limited to $750,000 over the R01 project period, with no more than $250,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this funding opportunity may not exceed three years.

PAR-25-179 Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). The purpose of this NOFO is to support confirmatory efficacy testing of non-pharmacological preventive and therapeutic interventions, and under certain conditions, selected pharmacological interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to, behavioural, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as non-invasive/transcranial) approaches, or a combination thereof. Pharmacological interventions to be studied under this grant mechanism are expected to primarily focus on drugs approved for marketing by the FDA (for any indication). These will include medications off-patent which are undergoing development for a new mental health indication. Confirmatory efficacy trials studying monotherapy, combination treatments, and stepped approaches, including multiple treatment modalities, may be supported. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action (target), a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the target mechanism and change in functional or clinical effects. Ultimately, this NOFO is intended to support a sufficiently powered efficacy trial to determine the intervention's potential for significant clinical benefit.

Date: February 14, 2025 through to October 15, 2027All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years; however, applicants are strongly encouraged to consider efficiencies and projects of shorter duration, as feasible.

PAR-25-181 Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). The purpose of this NOFO is to encourage pilot research developing and testing innovative

psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioural, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviours or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. The R33 is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention.
Date: February 18, 2025 through to October 15, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period, which may not exceed 3 years.

PAR-25-182 Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective, and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated with mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention.
Date: February 18, 2025 through to October 15, 2027All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

PAR-25-183 Early-Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). The purpose of this NOFO is to support the early-stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness. Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support early-stage testing of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioural effect. Paediatric, adult, and geriatric-focused interventions are appropriate for this NOFO. This R33 NOFO supports single-phased clinical trial awards. Applicants proposing high-risk projects are encouraged to apply to one of the companion NOFOs, PAR-25-184 or PAR-25-180.
Date: February 14, 2025 through to October 15, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 3 years.

PAR-25-184 Early-Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required). The purpose of this NOFO is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support evaluation of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult, and geriatric-focused interventions are appropriate for this NOFO.The R61/R33 NOFOs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-25-183.
Date: June 17, 2025 through to October 15, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

PAR-25-238 National Library of Medicine (NLM) Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional). NLM supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.
Date: June 05, 2025 through to January 07, 2026. All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are limited to $250,000 per year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

PAR-25-272 New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional). All applications are due by 5:00 PM local time of applicant organization. The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. Research can include healthy human participants of any age; specific clinical groups such those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data.
Date: June 16, 2025 through to February 16, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Direct costs are limited to $275,000 over the two-year project period. No more than $200,000 in direct costs are allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

PAR-25-279 New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional). The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and

aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages.
Date: June 05, 2025 through to February 05, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

PAS-25-161 HIV Prevention and Alcohol (R34 Clinical Trials Optional). This R34 Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement PA-25-187HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NIAAA expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention of HIV. In this NIAAA funding opportunity for pilot clinical trials the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a clinical trial and testing of intervention tools.
Date: May 07, 2025 through to May 07, 2026All applications are due by 5:00 PM local time of applicant organization.
Budget: The budget during the three-year project period may not exceed $450,000 direct cost, with no more than $225,000 direct cost requested in a single year. The project period is limited to 3 years.

PAS-25-208 HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.
Date: May 07, 2025 through to May 07, 2026All applications are due by 5:00 PM local time of applicant organization.
Budget: NIH intends to fund an estimate of 2 - 4 awards, corresponding to a total of $2,000,000, for fiscal year 2025. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

PAR-25-285 Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required). This NOFO complements NIMH's suite of clinical trial funding opportunities by supporting milestone-driven feasibility and infrastructure development (R61) research followed by well-powered clinical trials (R33) to test the effectiveness of system interventions or strategies that improve the organization, delivery, coordination, and outcomes of mental health care for priority populations. System interventions - which may span, for example, structural, policy, and organizational domains - attend to issues about the access, equity, engagement/utilization, value (cost/financing), management, or quality and safety of mental health services, with the goal of improved care processes and clinical, functional, or population level outcomes. Accordingly, the focus of system interventions may include multiple factors/levels related to care delivered within or across a variety of care settings, such as health systems and organizations, mental health and community clinics, schools, and social welfare or justice systems. Projects may test the impact of policies and practices, interventions to facilitate care transitions and continuity across settings, and interventions to improve linkages/coordination across systems. Researchers will have up to two years in the R61 phase to demonstrate feasibility and adequate infrastructure to justify conducting the main trial (R33). Applicants pursuing other stages of intervention development and testing should refer to companion NOFOs listed at Support for Clinical Trials at NIMH.

Date: June 17, 2025 through to October 15, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the project should determine the project period for each phase. The maximum period of the combined R61 and R33 phases cannot exceed 5 years, with a maximum of 2 years for the R61 phase and maximum of 4 years for the R33 phase of the project. Applicants are encouraged to streamline the project period to complete the research as efficiently as possible.

PAR-25-100 Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional). The purpose of this notice of funding opportunity (NOFO) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of tobacco or substance use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This NOFO provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.
Date: June 16, 2025 through to May 07, 2027. All applications are due by 5:00 PM local time of applicant organization.
Budget: Direct costs are limited to $450,000 over the 3-year project period, with no more than $225,000 in direct costs allowed in any single year. The total project period for an application submitted may not exceed three years.

Faculty of Medicine and Health Sciences
Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)
009 Kth Floor, Teaching Block, Tygerberg Campus.

Enquiries: fmhsgmo@sun.ac.za

Add "*Interest in NIH opportunity*" in the subject line.

Add the *notice number with hyperlink* in the text of the email.